REG - Avacta Group PLC - New Response in Phase 1b Trial

AvactaAnnouncement

19/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250619:nRSS5471Na&default-theme=true

RNS Number : 5471N  Avacta Group PLC  19 June 2025

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

New Response in the FAP-Dox (AVA6000) Phase 1b Trial

 

LONDON and PHILADELPHIA - June 19, 2025 - Avacta Therapeutics (AIM: AVCT), a
life sciences company developing innovative, targeted oncology drugs, today
announces a new partial response observed in a patient with salivary gland
cancer (SGC) in the dose expansion phase of the FAP-Dox (AVA6000) Phase 1b
trial.

 

This further signal of antitumor activity in this disease setting is
encouraging as the expansion cohort continues to enroll in the indication of
salivary gland cancer. This patient is a 69-year-old male with metastatic
salivary gland cancer.  His prior therapy includes surgery and radiation with
no prior systemic therapy.  His combined tumor diameter was reduced at the
first scan by almost 50%, qualifying as a partial response.

 

Recent data presented by the Company at the American Association of Cancer
Research (AACR) annual meeting in April 2025 described the Phase 1a cohort of
patients with one confirmed partial response and multiple minor responses with
a disease control rate of 91%. At the time of the data cutoff, the median
progression free survival had not been reached and the data are trending to a
doubling of the benchmark PFS in this pretreated setting. Recent benchmark
data were published at ESMO in 2024 (Licitra et al. ESMO Annual Congress
2024). The unmet need in this rare tumor type is very high, with metastatic
salivary gland cancer having no preferred standard therapy.

 

The Company plans to publish the final data from the AVA6000 Phase 1a in the
second half of 2025.  Further, the Company will provide a business update on
the date of the Annual General Meeting, on July 2, 2025.

 

 

Christina Coughlin, CEO Avacta commented:

 

"We are thrilled to see the antitumor activity of FAP-Dox (AVA6000) in this
disease with no preferred standard therapy.  The high unmet need in this
indication underscores the potential for FAP-Dox to have a meaningful impact
to patients.  We are encouraged by this response and remain focused on
delivering further updates in this setting later in 2025."

 

 

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                           www.avacta.com (https://avacta.com/)

 Michael Vinegrad, Group Communications

 Director

 Peel Hunt (Nomad and Joint Broker)

 James Steel / Chris Golden                                 www.peelhunt.com (http://www.peelhunt.com/)

 Panmure Liberum (Joint Broker)

 Emma Earl / Will Goode / Mark Rogers                       www.panmureliberum.com

 ICR Healthcare                                             avacta@icrhealthcare.com (mailto:avacta@icrhealthcare.com)

 Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 Investor Contact

 Renee Leck                                                 renee@thrustsc.com (mailto:renee@thrustsc.com)

 THRUST Strategic Communications

 Media Contact

 Carly Scaduto                                              Carly@carlyscadutoconsulting.com

                                                          (https://www.globenewswire.com/Tracker?data=YG-jwixFWaHByFwlhEr4NbVmhGc9YbrV0ozbiHY-33jDG-KDtaZDvqBLS4-5RgIi5zejtwvrLPO1U6xSYlV9BnK-dIegbuZft6wwj-ugstEWYrPDSrd9NwgKYBdm1l9Ty6VSa1gsRJqxeLaMfUN-easXzPVocBafm0xbzTKFahId-T7w4WgPYGYfKdFh6MGXNNniX0b0LrpQwjqHYj_mTmjerN3nRW6pwlbWejQ6wZCns0oke-U-WA7CB-Z2CD1ObedcWrqwKYgQwTY1NxAOLXtmHTL3VJ7HZ4Z3K9ZhB_2_vgbo4aKKTppE6l1bjU2w)
 Carly Scaduto Consulting

 

 

 

About Avacta - www.avacta.com (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies with the pre|CISION(®) platform.
pre|CISION(®) is a proprietary warhead delivery system based on a
tumor-specific protease (fibroblast activation protein or FAP) that is
designed to concentrate highly potent warheads in the tumor microenvironment
while sparing normal tissues. Our innovative pipeline consists of
pre|CISION(®) peptide drug conjugates (PDC) or Affimer(®) drug conjugates
(AffDC) that leverage the tumor-specific release mechanism, providing unique
benefits over traditional antibody drug conjugates.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGUGDLRXBDGUC